
|Articles|February 1, 2004
Phase III under way
New York - Adjuvant therapy with a macrophage-activating growth factor appears to prolong survival in high-risk melanoma, Lynn E. Spitler, M.D., said.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
The SkinCARE Questionnaire: Assessing the Psychological Dimensions of Skin Health Beyond Disease
4
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
5


















